X
Pharma Advancement
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

    AstraZeneca Eyes Acquisition To Develop Cell Therapies

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

    AstraZeneca Eyes Acquisition To Develop Cell Therapies

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Facilities & Operation

Bayer HealthCare launches oncology treatment Xofigo in UK

Yuvraj_pawp by Yuvraj_pawp
14th January 2014
in Facilities & Operation

Bayer HealthCare has launched Xofigo (radium – 223 dichloride) solution for injection in the UK to treat adults with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastases.

The launch follows a positive recommendation from the European Committee for Medicinal Products for Human Use and the marketing authorisation by the European Commission (EC) for Xofigo based on results from the Phase III ALSYMPCA (ALpharadin in SYMptomatic Prostate CAncer) trial.

In the UK, Prostate cancer is the most common cancer in men and in 2010, about 41,000 men were newly diagnosed with the disease. The company said that on average,10-20% of prostate cancer patients develop castration-resistant prostate cancer (CRPC) in about five years of follow up and 84% of them have metastatic disease at the time of diagnosis.

ALSYMPCA trial principal investigator and The Royal Marsden NHS Foundation Trust Consultant Clinical Oncologist Christopher Parker said, “The majority of men who develop castration-resistant prostate cancer will develop bone metastases which can be painful and even life-threatening.”

The clinical safety and efficacy of Xofigo have been assessed in a double-blind, randomized, placebo-controlled trial of Xofigo with best standard of care vs. placebo with best standard of care in symptomatic CRPC patients with bone metastases.

Around 921 patients in more than 100 centres in 19 countries were enrolled in the trial, which included about six intravenous injections of Xofigo or placebo each separated by an interval of four weeks.

Primary efficacy endpoint in the trial was overall survival (OS), while secondary endpoints included time to symptomatic skeletal events (SSE), alkaline phosphatase (ALP) and prostate-specific antigen progression (PSA).

Bayer Business Unit head Specialty Medicine Jon Hemphill said the launch and availability of Xofigo in the UK should be welcomed news for physicians and patients, who have been looking for new treatment options.

“With today’s announcement, we reinforce our commitment to working closely with physicians, patients and other stakeholders to meet the needs of this community,” Hemphill said.

According to the company, the trial was stopped early after a pre-planned efficacy interim analysis, following a recommendation from an Independent Data Monitoring Committee, on the basis of achieving improvement in overall survival.

At the interim analysis, Xofigo has improved OS, while median OS was 14.0 months with Xofigo plus best standard of care vs. 11.2 months with placebo plus best standard of care.

Additionally, there was a delay in the time to first SSE for patients treated with Xofigo vs. placebo. An updated analysis, carried out after the trial was unblinded, demonstrated a further improvement in OS for patients treated with Xofigo vs. placebo, with a median OS of 14.9 months vs. 11.3 months.

Xofigo also showed improvement in both analyses compared to placebo in the secondary endpoints of total time to ALP progression, time to PSA progression.

Previous Post

Some 'healthy' vegetable oils may actually increase risk of heart disease

Next Post

Tafinlar® receives FDA Breakthrough Therapy designation for non-small cell lung cancer with BRAF mutation

Related Posts

Pharmaceutical-Chemicals Market Booms with Rising API Demand
Asia

Pharmaceutical Chemicals Market Booms with Rising API Demand

28th May 2025
Clinical Trials

Oracle Wins the Asia Pacific Biopharma Excellence Awards

21st March 2025
Facilities & Operation

Robust Supply Chains Are Essential For Affordable Drugs

18th May 2024
Essential Elements of Quality Management In Lab Practices
Facilities & Operation

8 Essential Elements of Quality Management In Lab Practices

18th May 2024
Facilities & Operation

FDA Solidifies Its Authority Over Laboratory-Developed Tests

18th May 2024
Facilities & Operation

100% Renewable Electricity Record Hit By Charles River Labs

17th May 2024
Next Post

Tafinlar® receives FDA Breakthrough Therapy designation for non-small cell lung cancer with BRAF mutation

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In